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Abstract 
Self-assembly of small molecules or macromolecules through non-covalent or covalent bonds 
to build up supramolecular nanostructures is a prevalent and important process in nature. 
While  most  chemists  use  small  molecules  to  assemble  nanostructures  with  physical  or 
chemical perturbations, nature adopts enzymes to catalyze the reaction to assemble biolog-
ical,  functional  nanostructures  with  high  efficiency  and  specificity.  Although  enzymatic 
self-assembly of nanostructures has been remained challenging for chemists, there are still a 
few examples of using important enzymes to initiate the self-assembly of nanostructures for 
diagnosis or therapy of certain diseases because down-regulation or overexpression of cer-
tain enzymes always associates with abnormalities of tissues/organs or diseases in living body. 
Herein, we introduce the concept of enzymatic self-assembly and illustrate the design and 
application of enzyme-catalyzed or –regulated formation of nanostructures for theranostics. 
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Introduction 
Enzymes are a class of proteins that exhibit high 
efficiency and specificity when catalyzing a myriad of 
reactions in cellular environment [1]. Self-assembly is 
a prevalent process in nature which plays important 
roles in biology from maintaining the integrity of cells 
to  performing  cellular  functions  and  inducing  ab-
normalities that cause diseases [2-6]. Compared with 
physical or conventional chemical perturbations (e.g., 
pH,  temperature,  ionic  strength,  ligand-receptor  in-
teractions,  etc.)  for  initiating  the  self-assembly  pro-
cess, enzymatic regulation shows promising applica-
tions because it integrates the self-assembly with bio-
logical  events  [7-8].  Generally,  enzymatic 
self-assembly of small molecules into nanostructures 
includes two fundamental steps: the bond cleavage or 
formation of the precursors by the action of enzymes, 
and  the  self-assembly  of  the  amphiphilic  product 
generated  from  the  first  step  to  yield 
three-dimensional  fibrillar/spherical  nanostructures 
via  supramolecular  interactions  (π-π  interactions, 
hydrogen  bonding,  and  charge  interactions  among 
the molecules, among others). As the expression and 
dispersion of the so many kinds of enzymes vary in 
cells or in different parts at different states of a body, 
enzymatic self-assembly allows people to control the 
delivery,  function,  and  response  of  functional 
nanostructures according to a specific biological con-
dition  or  environment,  which  provides  accurate  in-
formation  about  the  health  condition  of  a  body  for 
diagnosis as well as therapy.  
Figure 1 shows an enzymatic self-assembly pro-
cess in cells. After entering the cell, the precursor with 
a substrate motif (normally a peptide sequence) for 
specific enzyme will be catalyzed by the enzyme (e.g., 
hydrolyzed  by  a  protease)  to  yield  the  amphiphilic 
product  which  self-assembles  into  nanostructures 
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inside  cells.  If  the  enzymatic  product  is  not  hydro-
phobic  enough  for  self-assembly,  Liang  and 
co-workers designed another oligomerization reaction 
to  generate  the  amphiphilic  oligomers  for 
self-assembly.  This  enzymatic  polymerization  and 
self-assembly can be used to trap an imaging agent (or 
drug) at the site of enzyme activity if optical proper-
ties (or therapeutic effect) of the new material are not 
strongly attenuated [9]. 
Nowadays,  nanomaterials  are  widely  used  for 
theranostics [11-15]. Why nanostructures? An obvious 
source of inspiration for the design of nanoscale ma-
terials from the bottom up is provided by Nature. Life 
has  produced  a  range  of  self-assembling  nanoscale 
systems based on lipids, nucleic acids and amino ac-
ids. In these systems, disordered mixtures of molecu-
lar building blocks spontaneously arrange themselves 
to form highly organized structures with well deﬁned 
properties.  Numerous  practical  examples  of 
self-assembly have long being existed in Nature, the 
5-6-nm-thick cell membrane to maintain the integrity 
of a cell, the 2-nm-wide DNA double stranded chains 
to store genetic information, and the 25-nm-wide mi-
crotubules to govern cellular mitosis, to name just a 
few [4]. Their small molecular precursors share some 
common features, such as amphiphilicity and supra-
molecular interactions, which provide us with direc-
tions on precursor design. 
The  specificity  of  enzyme  determines  that  one 
certain enzyme can only  be functional towards  one 
substrate or a class of compounds which share a sim-
ilar  structure.  A  vast  array  of  natural  enzymes  are 
known, most catalyze a deﬁned reaction but the de-
gree of speciﬁcity to their substrate varies from highly 
speciﬁc  to  non-speciﬁc.  Enzymatic  self-assembly, 
therefore, calls for rational design of a specific struc-
tured  substrate  to  be  recognized  by  the  certain  en-
zyme, either the same as its natural substrate or nat-
ural substrates derivatives. After enzyme catalyzing 
the synthesis of a molecule, or removing a blocking 
group from a molecule, the as-formed intermediates 
should have the tendency to aggregate and form more 
stable  nanostructures.  Peptides  have  been  exploited 
the  most  as  building  blocks  for  self-assembling  na-
nomaterials.  Table  1  gives  several 
enzymes  and  their  corresponding 
substrates that have been explored 
so far for experimental and clinical 
applications. 
 
 
 
Figure  1.  Schematic  illustration  of 
enzyme-controlled  polymerization 
and/or self-assembly of nanostructures 
in cells [9-10]. 
 
Table 1. Examples of enzymes, corresponding substrates, and potential applications of enzymatic self-assembly of 
nanostructures.  
enzyme(s)  substrate  applications 
alkaline phosphatase  Fmoc-Y-P(O)(OH)2  biomineralization [16] 
acid phosphatase  Fmoc-Y-P(O)(OH)2  inhibitor screening [17] 
phosphatase  Nap-βPhg-βPhg-Y-P(O)(OH)2  drug delivery [18] 
kinase/phosphatase switch  Nap-FFGEY-P(O)(OH)2  drug delivery [19] 
β-lactamase  Nap-FF-NH(CH2)2S-ACLH  assay bacteria [20] 
thermolysin  Fmoc-F and -FF  tissue engineering [21-22] 
esterase  Nap-FF-NH(CH2)2OCO(CH2)2CO2H   control the fate of cells [23] 
human tyrosine phosphatase  Nap-FFY-P(O)(OH)2  bacterial inhibition [7] 
caspase-3  Ac-DEVDC-CBT  cell apoptosis [9] 
furin  Ac-RVRRC-CBT  breast cancer [24] 
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Regarding enzymatically controlled self assem-
bling system based on peptides, two general catego-
ries are available, natural and unnatural. The former 
one utilizes the basic conformational units of naturally 
existence: proteins, β-sheets and turns, α-helices and 
coiled coils. The examination of protein sequences has 
made it possible for researchers to explore basic rules 
that promote the formation of one of the basic con-
formational units, which helps to create a sequence of 
the  peptides.  The  latter  category  usually  covalently 
links amino acids to other molecules, either an alkyl 
chain to form a peptide amphiphile, or to an aromatic 
group to create π-π interactions between the aromatic 
groups [25]. Design of other systems based on lipids, 
which primarily act as barriers, or polynucleic acid for 
information  storage  and  retrieval  mechanisms  has 
also been explored [26-27]. 
Enzymatic self-assembly of nanostructures 
for diagnosis 
Disease  often  comes  along  with  abnormal  ex-
pression of some enzymes, and the abnormality hap-
pens before the symptoms emerge. Since enzymatic 
self-assembly could assist people to examine the ex-
istence, content, and distribution of enzymes, which 
have close relationship with pathological changes, it 
has great potential to be applied to clinical diagnosis. 
Some recent examples of examining the irregular ex-
pression of enzymes are listed to illustrate the mech-
anisms for diagnosis. 
1. Caspase 3-controlled self-assembly of nano-
particles for detecting cell apoptosis.  
Many toxic agents, including most compounds 
used to treat cancer, induce apoptosis. Hence, factors 
that influence apoptotic cell death may contribute to 
the outcome of cancer therapy. Caspases are the exe-
cutioners of cell apoptosis, a major form of cell death. 
Activation of caspases during apoptosis results in the 
cleavage  of  critical  cellular  substrates,  including 
poly(ADP-ribose) polymerase and lamins, so precip-
itating  the  dramatic  stereotypic  morphological 
changes of cells [28]. Caspase-3, an important protease 
of  caspase  family,  is  tightly  associated  with  cell 
apoptosis.  Detection  of  caspase-3  activity  provides 
people  with  an  essay  of  assessing  the  chemothera-
peutic effect of anti-cancer drug during the treatment 
[29-30]. A peptide sequence, DEVD, is a specific sub-
strate for caspase-3 cleavage [31]. Inspired by this and 
employing  a  biocompatible  condensation  platform, 
Liang and co-workers designed a molecular probe for 
caspase-3  controlled  self-assembling  fluorescent  na-
noparticles to examine caspase-3 activity at low con-
centration  [32].  As  showed  in  figure  2,  the  probe    
Acetyl-Asp-Glu-Val-Asp-Cys(StBu)-Lys(Biotin)-CBT 
contains  a  DEVD  substrate  for  caspase-3  cleavage, 
disulfided cysteine motif for supplying 1,2-aminothiol 
group  for  condensation,  Lys(Biotin)  for  capturing 
FITC-labelled  streptavidin  (SA-FITC).  After  the  re-
duction  of  its  disulfide  bond  by 
tris(2-carboxyethyl)phosphine (TCEP) and removal of 
DEVD sequence by caspase-3 cleavage, the precursor 
yields an intermediate which condenses to form am-
phiphilic  dimmers  and  subsequently  self-assembles 
into  biotinylated  nanoparticles.  The  biotin  arms 
standing on the surface of the nanoparticles can cap-
ture the FITC-labelled streptavidin (SA-FITC) via the 
specific  interaction  between  biotin  and  streptavidin 
and turn on the fluorescence thereafter. Unlike other 
enzymatic  self-assembly  systems  which  need  hun-
dreds units  of enzyme and millimolar substrates  to 
launch the self-assembly, this protocol only requires 
several units of caspase-3 and micromolar substrates 
to self-assemble nanostructures (i.e., nanoparticles). In 
terms of caspase-3 detection on the other hand, this 
protocol  provides  people  with  a  new  method  of 
sensing the caspase-3 activity at lower concentrations 
and may find its potential application for evaluating 
the in vivo chemotherapeutic effect of an anti-cancer 
agents [33].  
 
Figure  2. A caspase-3 controlled condensation was applied to self-assemble biotinylated nanoparticles for capturing 
FITC-labelled streptavidin and subsequently turning on the fluorescence signal or on the other hand, detecting caspase-3 
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2. Furin-controlled self-assembly of nanoparticles 
for early detection of cancer.  
The trans-Golgi protease furin is a protein con-
vertase that plays crucial roles in homeostasis, and in 
diseases  ranging  from  anthrax  and  Ebola  fever  to 
Alzheimer’s  disease  and  cancer  [31,34-36].  Furin  is 
upregulated  in  several  cancers,  including 
non-small-cell lung carcinomas, squamous-cell carci-
nomas of the head and neck, and glioblastomas [37]. 
Moreover, the increase of furin in tumors correlates 
with an increase of membrane type 1 – matrix metal-
loproteinase  (MT1-  MMP),  one  of  furin’s  substrates 
[38-39]. MT1-MMP activates extracellular pro-MMP2 
to  induce  rapid  tumor  growth  and  metastasis  [40]. 
Thus, the overexpression of furin offers people with a 
useful hint of early development of certain cancers. 
One big advantage for chemists to study furin is that 
furin  preferentially  cleaves  Arg-X-Lys/Arg-Arg↓X 
motifs, where Arg is arginine, Lys is lysine, X can be 
any amino acid residue and ↓ indicates the cleavage 
site [41]. Inspired by this enzymatic reaction, Rao and 
co-workers designed a furin based macrocyclization 
reaction to self-assemble nanoparticles intracellularly 
for  imaging  furin  activity  in  cells  [24].  As  demon-
strated in figure 3, after entering a breast cancer cell 
MDA-MB-468  which  overexpresses  furin,  the  disul-
fide bond of a fluorescent probe 1 will be reduced by 
intracellular  glutathione  (GSH)  and  its 
Arg-Val-Arg-Arg  motif  will  be  cleaved  by  furin  to 
yield intermediate 2. Then the 1, 2-aminothiol group 
on  the  cysteine  motif  and  the  cyano  group  on  the 
2-cyano-6-hydroxyquinoline  motif  (CHQ)  of  2  will 
condense to initiate the intramolecular macrocycliza-
tion  and  yield  amphiphilic  product  3  which 
self-assembles  into  fluorescent  nanoparticles  at  the 
location of furin. Using a fluorescence microscope to 
record  this  intracellular  macrocyclization,  Rao  and 
co-workers successfully imaged furin activity in live 
cancer cells. 
 
 
 
Figure 3. Proposed enzyme-controlled (e.g., furin) macrocyclization reaction in cells. A cell-permeable probe 1 enters cells 
and is converted by reduction and/or enzymatic processing into an intermediate 2, which quickly undergoes intramolecular 
cyclization to generate the macrocyclic product 3. The self-assembly of 3 leads to the formation of nanoparticles accu-
mulated locally at or near the enzyme (e.g., furin) location in cells [24].  
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3. Enzyme-switch-regulated self-assembly of 
nanofibers for detecting the activities of kinase 
and phosphatase. 
Many  diseases  (e.g.,  cancer,  diabetes,  Alz-
heimer’s  disease,  and  multiple  sclerosis)  are  associ-
ated  with  the  abnormal  activities  of  phosphatases 
and/or  kinases  [42-45].  Conventional  protocols  for 
detecting the activities of phosphatases or kinases are 
immunoassays. For immunoassays, to detect the ac-
tivities of phosphatase and kinase as one pair at the 
same  time  is  time  consuming  and  instrumental  de-
pendent.  Therefore,  developing  a  simple  and  easy 
method  for  quick  measurement  of  the  activities  of 
phosphatase and kinase in vitro and even in vivo has 
remained challenging for  chemists. By carefully de-
signing  and  numerous  test,  Xu  and  co-workers  de-
veloped  a  self-assembly/disassembly  system  of  su-
pramolecular  hydrogel  (composed  of  nanofibers) 
based  on  phosphatase/kinase  switch  and  used  this 
system to detect the activities of phosphatase and ki-
nase in vitro and in vivo [19]. As shown in figure 4, 
they  designed  a  pentapeptidic  hydrogelator, 
Nap-FFGEY (1), which self-assembles into nanofibers 
and forms hydrogels at 0.6 wt %.  
 
 
 
Figure  4.  Schematic  illustration  of  a  phospha-
tase/kinase-switch-regulated  self-assembly/disassembly  of 
supramolecular hydrogel composed of nanofibers. Upper: 
Phosphorylation of the hydrogelator 1 under the action of 
ATP and kinase yields 2 and induces a gel-solution phase 
transition.  Dephosphorylation  of  2  under  the  action  of 
phosphatase generates 1 and launches the self-assembling of 
1 into nanofibers and the formation of hydrogels. Lower: 
Chemical structures of 1 and 2. 
 
When a kinase is added to the hydrogel in the 
presence of adenosine triphosphates (ATP), the cor-
responding phosphate of 1 (i.e., 2) is generated, which 
disrupts the self-assembly to induce a gel-sol phase 
transition. Once the resulting solution is treated with 
a phosphatase, dephosphorylation of 2 yields the hy-
drogelator 1, thus restoring the self-assembly of 1 to 
form the hydrogel of nanofibers. By subcutaneously 
injecting  the  solution  of  2  into  mice,  Xu  and 
co-workers  also  successfully  demonstrated  this  en-
zymatic conversion (i.e., from 2 to 1 under that action 
of phosphatase) and self-assembly of the enzymatic 
product to form nanofiber-based hydrogel in vivo. 
Enzymatic self-assembly of nanostructures 
for therapy 
The ultimate goal of scientific research is to serve 
us human-beings. Therefore, practical discoveries that 
can be applied to clinical treatment are much more 
valued. Up to date, a lot of precursors (or pro-drugs) 
based on enzymatic self-assembly  have been devel-
oped  to  treat  various  kinds  of  diseases,  especially 
cancers. The mechanisms of these disease treatments 
are either using enzymatic self-assembled nanostruc-
tures to disrupt the intracellular environment of the 
cytosol,  or  locally  enhancing  the  concentration  of  a 
drug after enzymatic self-assembly, or self-assembling 
nanostructures  as  enzyme  inhibitor.  Nevertheless, 
they share a common feature that the self-assembly of 
nanostructures  are  under  the  catalysis  of  the 
over-expressed  enzymes  which  correlate  with  the 
occurrence of a certain disease. Here are some exam-
ples listed below. 
1. Esterase based self-assembly of nanofibers for 
regulating cell death. 
It was reported that some highly invasive mela-
noma cell lines (e.g., MUM-2B) secret high levels of 
active  urokinase  and  esterase  [46].  As  mentioned 
above, intracellular artificial nanostructures can affect 
cellular behavior, and might induce cell death in the 
end.  As  shown  in  figure  5,  Xu  and  co-workers  de-
signed  a  proper  precursor  which  doesn’t 
self-assemble  extracellularly.  After  entering  HeLa 
cells by perfusion, the precursor is converted into a 
hydrogelator by an endogenous enzyme (esterase in 
here)  and  self-assembles  into  nanofibers.  The  for-
mation  of  nanofibers  induces  hydrogelation,  which 
exerts stresses on the cell, and causes cell death [23]. 
To  proof  that  the  death  of  HeLa  cells  is  caused  by 
formation of intracellular nanofibers and hydrogela-
tion,  Xu  and  co-workers  observed  the  intracellular 
nanofibers  formed  with  the  hydrogelator  under  a 
transmission  electron  microscope  (TEM).  Moreover, Theranostics 2012, 2(2) 
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they incubated normal fibroblast cells NIH3T3 with 
the  precursor  at  the  same  concentration  and  found 
that  the  precursor  doesn’t  show  any  toxicity  to  the 
cells. Treating the two cell lines with an esterase in-
dicator, Xu and co-workers found that the expression 
of esterase in HeLa cells is much higher than that in 
NIH3T3 cells, which proofs the death of HeLa cells is 
caused  by  intracellular  esterase-controlled 
self-assembly of nanofibers and hydrogelation there-
after.  
2. Phosphatase based self-assembly of taxol nan-
ofibers for cancer therapy. 
Taxol, an effective anti-cancer drug widely being 
used  in  clinic,  is  a  well-established  antineoplastic 
agent that binds specifically to the β-tubulin subunit 
of microtubules (MT) to arrest mitosis and result in 
programmed  cell  death  (i.e.,  apoptosis)  and  has 
shown remarkable activity in the treatment of breast, 
lung,  ovarian,  bladder  and  head  and  neck  cancers 
[47]. Because of its hydrophobicity, effective delivery 
of taxol to target tissues/organs without compromis-
ing  its  therapeutic  effect  has  been  remained  chal-
lenging  for  pharmaceutics.  Xu  and  co-workers  de-
veloped  an  enzymatic  self-assembly  system  to  for-
mulate this highly hydrophobic drug into an aqueous 
form (i.e., hydrogel) without comprising its activity 
for cancer therapy  [48]. As shown in figure 6, they 
covalently connect taxol with a motif that is prone to 
self-assemble  to  generate  the  hydrophilic  precursor 
(5a). Upon phosphatase cleavage, 5a changed into the 
hydrogelator  (5b)  which  self-assembled  into  nano-
fibers without compromising the cytotoxicity of the 
taxol on HeLa cells. This approach promises a general 
method  of  enzymatic  self-assembly  to  create  nano-
fibers of therapeutic molecules that have a dual role, 
as both the delivery vehicle and the drug for chemo-
therapy. 
 
 
 
 
Figure 5. Left: Schematic intracellular formation of nano-
fibers  that  leads  to  hydrogelation  and  cell  death.  Right 
upper: The chemical structures of the precursor and the 
hydrogelator. Right lower: Optical image of dead HeLa cells 
induced  by  intracellular  self-assembly  of  nanofibers  and 
hydrogelation.  
 
 
 
 
 
 
Figure 6. Schematic illustration of the design of the precursor (taxol derivative, 5a), enzymatic cleavage of 5a by phos-
phatase to yield the hydrogelator (5b) which self-assembles into supramolecular hydrogel based on taxol nanofibers. 
Compared with that of taxol itself, both the precursor 5a and the hydrogelator 5b did not show compromised cytotoxicity 
on HeLa cells.  
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3. Thermolysin catalyzed self-assembly of nano-
fibers for immobilizing laminin to treat ECM 
diseases. 
Genetic  diseases  of  the  extracellular  matrix 
(ECM)  have  brought  a  considerable  burden  to  our 
society. Most ECM diseases are identified as the result 
of a loss of function or a dominant negative effect of a 
single ECM protein mutated. A large number of ECM 
diseases  including  merosin  deficient  congenital 
muscular  dystrophy  (MDC1A)  characterized  by  the 
symptom of loss of adhesion between cells are caused 
by  mutations  within  the  members  of  laminin  gene 
family  [49].  In  order  to  treat  ECM  diseases,  ap-
proaches including directly intramuscular delivery of 
free  laminin  to  restore  correct  ECM  function  have 
been proposed [50-51]. However, this traditional ap-
proach is hampered by rapid transport of the injected 
free laminin away from the desired site of action, and 
incorporation into non-target tissues such as the mi-
crovasculature  of  the  brain  [52].  Williams  and 
co-workers reported a new method of controlled de-
livery  of  laminin  in  an  immobilized  form  [53].  As 
shown in figure 7, this system uses a protease enzyme 
(i.e.,  thermolysin)  to  act  via  reverse  hydrolysis  to 
produce  fluorenylmethoxycarbonyl  (fmoc) 
N-terminally  derivatized  tripeptide  for 
self-assembling nanofibers. Entangled nanofibers at a 
large  scale  produce  a  clear  hydrogel.  This 
3-dimensional network of nanofiber bundles enables 
the  three  dimensional  distribution  of  laminins 
throughout the structure. They proposed that laminin 
binds with the residues of leucine on the nanofiber 
bundles via the formation of barrel-like structure ra-
ther than through simple electrostatic interactions. In 
order to study the stability and suitability of this type 
of material for in vivo application, they also utilized 
microinjection  to  deliver  this  material  into  a  dys-
trophic zebrafish model which lacks laminin as a re-
sult  of  genetic  mutation.  Results  indicated  that  the 
biomaterial  remains  structurally  stable,  and  is  con-
fined spatially to the site of injection.  
 
 
 
Figure 7. Thermolysin catalysed peptide Self-Assembly. A) Fmoc-amino acid reacts with a dipeptide in the presence of the 
enzyme, to yield the hydrogelator fmoc-tripeptide. B) The side chain, R, is Leucine. C) Schematic for the formation of a 
fmoc-tripeptide from disordered solution phase fmoc amino acids (blue) and dipeptide (green) to yield an fmoc-tripeptide 
building block. These interact though hydrophobic and hydrogen bonding interactions, yielding a nanoscale tubular struc-
ture. These align longitudinally, yielding a matrix which induces a gel/sol transition. The forward reaction (black arrows) and 
backward (red) take place to establish equilibrium. D) In the case of immobilized enzyme, localization of catalytic activity 
physically separating the assembled fmoc-tripeptide, preventing further reactions.  
 
Conclusions 
Enzymes, self-assembly, and nanostructures are 
probably  the  most  common  features  of  a  cell  and 
clearly associated with its behavior. Using enzymes to 
self-assemble nanostructures for diagnosis and ther-
apy, we are just inspired by Nature and employ the 
knowledge of chemical biology to mimic the behavior 
of a cell and try our best to understand the mechanism 
of its function. Although a lot of methods have been 
successfully developed and utilized and some of them 
are explained here, there are still vast areas to be ex-
ploited considering the number of proteins in a single 
cell is up to one million. To get a better understanding 
of cellular behavior or a better theranostic outcome, 
people  need  multiple-enzyme  or  multiple-step  in-
volved self-assembly systems to build up more subtle, 
efficient  probes/drugs  for  diagnosis/therapy,  as 
Liang’s and Xu’s work listed in this paper. The fea-
tures  of  these  proposed  probes/drugs  are  neither Theranostics 2012, 2(2) 
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confined to the shapes as fiber or particle, nor sizes as 
nano-scale  or  micro-scale.  They  will  have  similar 
shapes  and  sizes  as  targeted  proteins  and  simulate 
their behavior, participate or involve in the cell cycle 
during the development of a disease, and eventually 
treat the disease. 
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